Optimizing sodium-glucose co-transporter 2 inhibitor use in patients with heart failure with reduced ejection fraction: A collaborative clinical practice statement

Heart failure with reduced ejection fraction (HFrEF) is a debilitating disease that is associated with substantial morbidity, mortality, and societal costs. The past three decades have brought about significant advancements in the pharmacologic management of HFrEF, and a corresponding reduction in m...

Descripción completa

Detalles Bibliográficos
Autores principales: Warden, Bruce A., Steiner, Johannes, Camacho, Albert, Nguyen, Khoa, Purnell, Jonathan Q, Barton Duell, P., Craigan, Courtney, Osborn, Diane, Fazio, Sergio
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2021
Materias:
Practice Guideline
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8315663/
https://www.ncbi.nlm.nih.gov/pubmed/34327503
http://dx.doi.org/10.1016/j.ajpc.2021.100183

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8315663/
https://www.ncbi.nlm.nih.gov/pubmed/34327503
http://dx.doi.org/10.1016/j.ajpc.2021.100183

Ejemplares similares